What Happened?
Seattle, WA-based Ben Bergo as Chief Executive Officer
About the Company
Nohla Therapeutics is a cellular therapy company driven to provide leading off the shelf therapies for patients with critical diseases. Nohla’s first product is a universal donor cell therapy targeting hematopoietic recovery and chemotherapy induced neutropenia, and is being extended to treat a range of other medical indications. This and other products in the pipeline are based on a unique umbilical cord blood expansion platform developed at the Fred Hutchinson Cancer Research Center
About the Person
Ben is the Chief Executive Officer of Nohla Therapeutics where he has played a pivotal role in leading the business strategy, corporate transactions and building the executive team. Prior to this role he was the Executive Chairman of Cytomatrix Limited, a company engaged in early stage stem cell expansion research. Ben previously co-founded and served as Managing Director of a privately financed diagnostics company with technology in-licensed from Harvard University. Ben worked for close to five years in venture capital where he held executive roles in portfolio companies and prior served in operating roles at Vision Systems Limited until its acquisition by Danaher Corporation in 2006.
Info Source
News
Short Profile